ACAD
32.59
-0.76
-2.28%
AEMD
0.227
-0.013
-5.417%
APRI
1.87
-0.05
-2.60%
ARNA
4.37
-0.11
-2.46%
ATEC
1.45
+0.04
+2.84%
CNAT
7.12
-0.41
-5.44%
CRXM
0.195
0.00
0.00%
CYTX
1.18
-0.02
-1.67%
DXCM
62.34
+0.36
+0.58%
GNMK
12.98
-0.32
-2.41%
HALO
14.28
+0.28
+2.00%
ILMN
185.64
-1.98
-1.06%
INNV
0.14
-0.04
-21.74%
INO
8.16
-0.17
-2.04%
ISCO
0.058
-0.001
-1.1966%
ISIS
63.67
-1.14
-1.76%
LGND
77.11
+0.88
+1.15%
LPTN
2.47
0.00
0.00%
MBVX
1.87
+0.01
+0.54%
MEIP
1.79
+0.04
+2.29%
MNOV
3.5
-0.09
-2.51%
MRTX
29.32
+0.21
+0.72%
MSTX
0.485
-0.012
-2.513%
NBIX
39.71
-1.82
-4.38%
NUVA
45.99
-0.41
-0.88%
ONCS
0.335
-0.015
-4.286%
ONVO
3.54
+0.17
+5.04%
OREX
7.83
+0.08
+1.03%
OTIC
35.36
-0.27
-0.76%
QDEL
26.98
-0.52
-1.89%
RCPT
164.89
+4.84
+3.02%
RGLS
16.94
-0.32
-1.85%
RMD
71.78
+0.13
+0.18%
SCIE
0.03
0.00
+17.65%
SPHS
0.579
+0.029
+5.2545%
SRNE
11.56
+0.2
+1.76%
TROV
6.81
-0.19
-2.71%
VICL
0.945
+0.045
+4.9889%
VOLC
17.99
0.00
0.00%
ZGNX
1.37
0.00
0.00%
ACAD
32.59
-0.76
-2.28%
AEMD
0.227
-0.013
-5.417%
APRI
1.87
-0.05
-2.60%
ARNA
4.37
-0.11
-2.46%
ATEC
1.45
+0.04
+2.84%
CNAT
7.12
-0.41
-5.44%
CRXM
0.195
0.00
0.00%
CYTX
1.18
-0.02
-1.67%
DXCM
62.34
+0.36
+0.58%
GNMK
12.98
-0.32
-2.41%
HALO
14.28
+0.28
+2.00%
ILMN
185.64
-1.98
-1.06%
INNV
0.14
-0.04
-21.74%
INO
8.16
-0.17
-2.04%
ISCO
0.058
-0.001
-1.1966%
ISIS
63.67
-1.14
-1.76%
LGND
77.11
+0.88
+1.15%
LPTN
2.47
0.00
0.00%
MBVX
1.87
+0.01
+0.54%
MEIP
1.79
+0.04
+2.29%
MNOV
3.5
-0.09
-2.51%
MRTX
29.32
+0.21
+0.72%
MSTX
0.485
-0.012
-2.513%
NBIX
39.71
-1.82
-4.38%
NUVA
45.99
-0.41
-0.88%
ONCS
0.335
-0.015
-4.286%
ONVO
3.54
+0.17
+5.04%
OREX
7.83
+0.08
+1.03%
OTIC
35.36
-0.27
-0.76%
QDEL
26.98
-0.52
-1.89%
RCPT
164.89
+4.84
+3.02%
RGLS
16.94
-0.32
-1.85%
RMD
71.78
+0.13
+0.18%
SCIE
0.03
0.00
+17.65%
SPHS
0.579
+0.029
+5.2545%
SRNE
11.56
+0.2
+1.76%
TROV
6.81
-0.19
-2.71%
VICL
0.945
+0.045
+4.9889%
VOLC
17.99
0.00
0.00%
ZGNX
1.37
0.00
0.00%
Home » Archive by Category

Xconomy

Alnylam CEO: More Cash in Hand Is to Fuel Expansion From Within

January 21, 2015 – 12:03 pm

Biotechs keep cashing in. The latest is Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY), which is entering the most critical juncture in its 13-year history as it tries to enter the…

[[Click headline to continue reading.]]

Crowdfunding is Banging on Biotech’s Door. Will We Let It In?

January 21, 2015 – 4:30 am

In the summer of 2013, the medical device startup Scanadu made headlines around the world when Scout, its handheld medical diagnostic tool for consumers, raked in an astounding $1.6 million on the…

[[Click headline to continue reading.]]

Crowdfunding is Banging on Biotech’s Door. Will We Let It In?

January 21, 2015 – 4:30 am

In the summer of 2013, the medical device startup Scanadu made headlines around the world when Scout, its handheld medical diagnostic tool for consumers, raked in an astounding $1.6 million on the…

[[Click headline to continue reading.]]

Crowdfunding is Banging on Biotech’s Door. Will We Let It In?

January 21, 2015 – 4:30 am

In the summer of 2013, the medical device startup Scanadu made headlines around the world when Scout, its handheld medical diagnostic tool for consumers, raked in an astounding $1.6 million on the…

[[Click headline to continue reading.]]

What President Obama’s Precision Medicine Initiative Might Include

January 21, 2015 – 2:04 am

In case you missed it, President Obama used his State of the Union speech Tuesday night to call for a national “precision medicine” initiative. But, as often happens in these Halloween…

[[Click headline to continue reading.]]

What President Obama’s Precision Medicine Initiative Might Include

January 21, 2015 – 2:04 am

In case you missed it, President Obama used his State of the Union speech Tuesday night to call for a national “precision medicine” initiative. But, as often happens in these Halloween…

[[Click headline to continue reading.]]

In the Jiu-Jitsu Match of Biotech Risk, a Reminder of Other Paths

January 20, 2015 – 4:07 pm

Risk makes for great headlines. I’m guilty as charged. My first column for Xconomy questioned whether biotech venture capitalists were losing relevance, running away from risk in an inherently…

[[Click headline to continue reading.]]

In the Jiu-Jitsu Match of Biotech Risk, a Reminder of Other Paths

January 20, 2015 – 4:07 pm

Risk makes for great headlines. I’m guilty as charged. My first column for Xconomy questioned whether biotech venture capitalists were losing relevance, running away from risk in an inherently…

[[Click headline to continue reading.]]

J.P. Morgan 2015: Notes, Thoughts, And Conversations From the Vortex

January 16, 2015 – 2:28 pm

The word “story” gets ill treatment at events like the J.P. Morgan Healthcare Conference. It often means an elevator pitch from a harried CEO to a distracted investor, or a few…

[[Click headline to continue reading.]]

J.P. Morgan 2015: Notes, Thoughts, And Conversations From the Vortex

January 16, 2015 – 2:28 pm

The word “story” gets ill treatment at events like the J.P. Morgan Healthcare Conference. It often means an elevator pitch from a harried CEO to a distracted investor, or a few…

[[Click headline to continue reading.]]